Cerebrolysin protocol

Pulsed course

Course (10–20 days)

~33u (0.33 mL)

~10 mg (research-vial basis) · Daily

SubQ or IM. Max 5 mL per IM site for clinical solution; research-vial volumes are small.

Rest

2–8 weeks

Pulsed courses let neurotrophic effects consolidate between rounds.

Phase	How often	Dose	Units	Notes
Course (10–20 days)	Daily	~10 mg (research-vial basis)	~33u (0.33 mL)	SubQ or IM. Max 5 mL per IM site for clinical solution; research-vial volumes are small.
Rest	2–8 weeks	–	–	Pulsed courses let neurotrophic effects consolidate between rounds.

Units column is labelled “Units (30 mg/mL)” on the page.

Cycle & timing

Cycle: 10–20 day courses separated by 2–8 week rests; several courses per year is the clinical pattern.

Timing: Daytime (can be mildly activating).

Where: SubQ abdomen, or IM. Rotate. (Clinical use is IV/IM.)

What to expect

Gradual cognitive/recovery support over a course; effects build across pulsed cycles. Best evidence is in stroke/dementia/TBI populations.

How much to buy

For 20-day course @ ~10 mg/day, research-vial basis:

~4

× 60mg vials

Men & women

Unisex neurotrophic mixture, dosed by protocol, not sex; used in both sexes in stroke/dementia trials. Avoid in pregnancy.

Dilution calculator

Set to the guide's typical mix for Cerebrolysin. Change anything to see where to draw.

Vial size

BAC water added

Dose you want

Draw to

33.3u

Volume

0.33 mL

Strength

30 mg/mL

Doses per vial

6

Assumes a U-100 insulin syringe (100 units = 1 mL). Double-check against the compound's page before you draw.

Recommended mixes

Vial	Water	Strength
60 mg	2 mL	30 mg/mL

60 mg: 1 unit = 0.3 mg. Research-vial format (not the 215 mg/mL clinical ampoule).

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, use within 2–4 weeks. Protect from light.

Don't use if: Epilepsy / seizure disorders (status epilepticus reported with grand mal) · Severe renal impairment · Pregnancy and lactation · Known hypersensitivity

Stop if you notice

Any seizure activity
Allergic reaction (rash, swelling, difficulty breathing)
Persistent agitation or insomnia

Side effects

Usually mild, injection-site reaction, headache, feeling hot/agitated if dosed late. Rare hypersensitivity.

Drug interactions

MAO inhibitors / antidepressants: additive effects, use caution. Do not mix in the same syringe with balanced amino-acid solutions.

Labs

None routinely required; renal function if impaired. Cognitive/functional tracking across courses.

What these labs mean →

Warnings

May lower seizure threshold, avoid in epilepsy. Rare allergic/hypersensitivity reactions (porcine-derived). Agitation/insomnia if dosed late in the day. Research-vial format is not equivalent to the clinical solution dose.

Patient education

Used in pulsed courses, not continuously. Dose earlier in the day to avoid sleep disruption. Avoid if you have a seizure disorder. Research vials are weaker than the pharmaceutical solution, set expectations accordingly.

These apply on top of the universal safety rules.

Pairs well with

Semax / Selank

cognitive synergy

Semax Selank

P21

neurogenesis

P21 (P021)

NAD+

mitochondrial support

NAD+

Avoid with

Epilepsy / seizure disorders

can lower threshold

Severe renal impairment

Pregnancy

Can Cerebrolysin + Semax share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

What it does

Cerebrolysin is a porcine-brain-derived peptide preparation with neurotrophic activity resembling BDNF/CNTF/GDNF. It supports neuronal survival, neuroplasticity, and repair. Clinically given as pulsed courses (e.g. daily for 10–20 days, then a rest). Note: pharmaceutical Cerebrolysin is a concentrated solution dosed in mL (grams/day); research-vial formats are far smaller microdoses.

Dose reality

Pharmaceutical Cerebrolysin is dosed at 5–30 mL of a 215 mg/mL solution (1–6 g/day); the mg-format research vials here deliver far less, manage expectations accordingly.

References

researchdosing peptidedosages PubMed thepeptidereport

From the guide, page 26.